Document is current
Any future updates will be listed below
-
Authors
Bowlus, Christopher
Levy, Cynthia
Kowdley, Kris V.
Kachru, Nandita https://orcid.org/0000-0002-2754-0723
Jeyakumar, Sushanth
Rodriguez-Guadarrama, Yael
Smith, Nathaniel
Briggs, Andrew
Sculpher, Mark
Ollendorf, Daniel
-
Funding
Funding for this research was provided by:
Gilead Sciences (N/A)
- License Information
-
More Information
Article History
Received: 25 October 2023
Accepted: 6 March 2025
First Online: 18 March 2025
Declarations
:
: Not applicable.
: Not applicable.
: CB has received grant funding and advisor fees from CymaBay Therapeutics, GSK, and Ipsen Bioscience; and has received grant funding from Boston Scientific, Calliditas Therapeutics, Cara Therapeutics, Chemomab, COUR Pharmaceuticals, Gilead Sciences, Hanmi Pharmaceuticals, Intercept Pharmaceuticals, Mirum Pharmaceuticals, Novo Nordisk, Pliant Therapeutics, and Viking Therapeutics; and has received advisor fees from Invea Therapeutics. CL has received grant funding and consultant fees from Calliditas Therapeutics, CymaBay Therapeutics, Gilead Sciences, GSK, Intercept Pharmaceuticals, Ipsen Bioscience, and Pliant Therapeutics; and has received grant funding from Cara Therapeutics, Escient Pharmaceuticals, GENFIT, HighTide Therapeutics, Mirum Pharmaceuticals, Novartis, and Zydus Lifesciences. KVK has received grant funding and consultant fees from CymaBay Therapeutics, GENFIT, Gilead Sciences, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Mirum Pharmaceuticals, NGM Biopharmaceuticals, Pfizer, and 89Bio; has received consultant fees from Enanta Pharmaceuticals, HighTide Therapeutics, and Inipharm; has received grant funding from Corcept Therapeutics, GSK, Hanmi Pharmaceutical, Novo Nordisk, Pliant Therapeutics, Terns Pharmaceuticals, and Viking Therapeutics; has received speaker bureau honoraria from AbbVie, Gilead Sciences, and Intercept Pharmaceuticals; and has stock options with Inipharm. NK is an employee of, and has stock options with, Gilead Sciences. SJ, YR, and NS are employees of Maple Health Group who conducted/executed the study on behalf of Gilead Sciences and were paid by Gilead Sciences for their services. AB and MS have received consultant fees from Gilead Sciences. DO has received consultant fees from Gilead Sciences and is employed at a research center that accepts sponsorship funding for its databases from life sciences companies, government agencies, and academic institutions.
